Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck
Authors:
- John D. HainsworthJHJohn D. Hainsworth
- Howard A. BurrisHBHoward A. Burris
- Dianna ShipleyDSDianna Shipley
Open Access
Abstract
BACKGROUND: The authors evaluated the feasibility, toxicity, and efficacy of gefitinib added to first‐line combined‐modality therapy for patients with locally advanced squamous carcinoma of the head and neck.METHODS: Patients with biopsy‐proven locally advanced squamous carcinoma of the head and neck who had low expected cure rates with local treatment modalities alone were eligible for this treatment. All patients received a 6‐week induction course of docetaxel, carboplatin, infusional 5‐fluorouracil, and gefitinib (250 mg daily). Gefitinib was continued while patients received concurrent weekly docetaxel and radiation therapy. After the completion of radiation therapy, gefitinib was continued until patients developed disease progression or for a maximum of 24 months.RESULTS: Sixty‐two patients (53% with stage IV disease) received protocol treatment, and 50 patients (81%) were able to complete the regimen. The addition of gefitinib increased the incidence of grade 3/4 mucositis (27%) and diarrhea (16%) during induction therapy but did not appear to add substantially to toxicity during concurrent chemoradiation. The estimated 3‐year progression‐free and overall survival rates for the entire group were 41% and 54%, respectively.CONCLUSIONS: The addition of gefitinib was associated with a moderate increase in toxicity with this combined modality regimen, particularly during induction therapy. Although this regimen was efficacious, the survival results overlap with results reported with chemoradiation alone. The role of epidermal growth factor receptor inhibitors in first‐line, combined‐modality therapy for patients with head and neck cancer remains undefined. Cancer 2009. © 2009 American Cancer Society.Keywords
Funding Information
- AstraZeneca
- Sanofi-Aventis
This publication has 20 references indexed in Scilit:
- Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based TherapyJournal of Clinical Oncology, 2007
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality ParadigmJournal of Clinical Oncology, 2006
- Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 2005
- Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck CancerJournal of Clinical Oncology, 2005
- Apport des méta-analyses sur données individuelles au traitement des cancers ORLCancer/Radiothérapie, 2005
- Randomized Phase III Trial of Neoadjuvant Chemotherapy in Head and Neck Cancer: 10-Year Follow-UpJNCI: Journal of the National Cancer Institute, 2004
- Docetaxel, cisplatin, and 5‐fluorouracil‐based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neckCancer, 2003
- Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neckCancer, 2002
- Induction Paclitaxel, Carboplatin, and Infusional 5-FU Followed by Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced Head and Neck CancerThe Cancer Journal, 2002